Enter multiple symbols separated by commas

Merck Profit Beats Estimates As Sales of New Drugs Jump

Pharmaceutical giant Merck said quarterly earnings rose as booming sales of newer medicines offset declines in older products, and said it plans to seek U.S. approval in 2009 for a migraine-headache treatment now entering late-stage trials.

Merck, which on April 12 preannounced the quarterly earnings trends, posted first-quarter net earnings of $1.7 billion, or 78 cents a share, compared with $1.52 billion, or 69 cents a share, a year earlier.

Merck earned 84 cents a share excluding restructuring charges, matching its forecast of last week.

Company sales rose 7% to $5.8 billion, fueled by surging revenue from its newer cholesterol fighters Zetia and Vytorin, new vaccines and the new Januvia diabetes treatment, as well as from strong sales growth of asthma drug Singulair and treatments for high blood pressure.

Merck said its migraine drug MK-0974, a so-called calcitonin gene-related peptide (CGRP) antagonist, is now entering Phase III trials. Data from mid-stage trials of the product will be unveiled at a medical meeting in June, the drugmaker said.

Combined sales of Vytorin and Zetia, which are marketed in partnership with Schering-Plough , grew 47% to $1.2 billion. Singulair sales jumped 25 percent to $1 billion, while combined sales of hypertension drugs Cozaar and Hyzaar rose 14 percent to $798 million. Januvia, a pill introduced in October, posted quarterly sales of $87 million.

Total sales of vaccines -- including Gardasil to prevent cervical cancer and Rotateq to protect against rotavirus infections in young children -- more than tripled to $903 million.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • Hero miles for military members: Real estate magnate's plea

    Chairman of the Fisher House Foundation, Ken Fisher, discusses the Hero Miles program with CNBC's Dina Gusovsky. During Military Appreciation Month, Fisher is asking every traveler to donate 1,000 of their miles to replenish the Hero Miles programs that is in danger of running out.

  • Cramer shuts down this market's haters

    "Mad Money" host Jim Cramer on why this market can't stop, won't stop.

  • From the battlefield to the boardroom

    Your Grateful Nation is dedicated to helping Special Forces veterans enter the corporate world and Knot Standard provides complimentary suits to vets. Mad Money's Jim Cramer spoke with Rob Clapper, Your Grateful executive director; John Ballay, Knot Standard co-founder and president; Tej Gill, retired U.S. Navy Seal; and Darren McB, active duty U.S. Navy Seal.